New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
06:33 EDTONCYOncolytics Biotech collaborators present head, neck cancer biomarker poster
Oncolytics Biotech announced that a poster authored by Bolton, et al was presented at the 8th Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein, or YAP-1, in head and neck cancer," covered preclinical research focused on identifying biomarkers predictive of sensitivity/resistance to reovirus in head and neck cancer cell lines. Researchers examined reovirus in panels of head and neck cancer cell lines to determine their sensitivity to reovirus-induced oncolysis. The study results showed that high YAP-1 protein expression correlated with reovirus resistance, whereas low YAP-1 expression correlated with sensitivity to reovirus infection. They also indicated that knocking the YAP-1 gene down resulted in certain cells becoming significantly more sensitive to reovirus infection. The researchers concluded that YAP-1 is a possible biomarker for sensitivity/resistance to reovirus infection in head and neck cancer and that further investigation into the crosstalk between chemical signaling pathways upstream and downstream of YAP-1 and its cellular localization, is important in understanding how it may be impeding reovirus oncolysis.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
06:34 EDTONCYOncolytics to present survival data from lung cancer candidate reolysin
Subscribe for More Information
August 26, 2015
06:33 EDTONCYOncolytics completes enrollment in Phase II lung cancer study of Reolysin
Subscribe for More Information
06:32 EDTONCYOncolytics completes enrollment in Reolysin Phase II study
Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with previously treated advanced or metastatic non-small cell lung cancer, or NSCLC. The trial is being sponsored and conducted by the NCIC Clinical Trials Group, or NCIC CTG, at Queen's University in Kingston, Ontario. The primary objective of the trial is to evaluate the effect of Reolysin in combination with standard salvage chemotherapy on the progression free survival of patients with advanced or metastatic non-small cell lung cancer. The secondary objectives are to determine the tolerability and toxicity of the therapeutic combination; to investigate additional potential measures of efficacy, including progression rates at three months, objective response rate and overall survival; and to explore potential molecular factors predictive of response. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use